Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
Novartis
Novartis
Memorial Sloan Kettering Cancer Center
Roswell Park Cancer Institute
Genmab
Genmab
Autolus Limited
Genmab
Genmab
Hoffmann-La Roche
Bristol-Myers Squibb
Eastern Cooperative Oncology Group
Pfizer
Acerta Pharma BV
Dana-Farber Cancer Institute
Taiho Oncology, Inc.
M.D. Anderson Cancer Center
Hoffmann-La Roche
Galapagos NV
Allogene Therapeutics
Monte Rosa Therapeutics, Inc
Hoffmann-La Roche
Servier
City of Hope Medical Center
Celgene
Seattle Children's Hospital
Memorial Sloan Kettering Cancer Center
Big Ten Cancer Research Consortium
Dana-Farber Cancer Institute
Tanabe Pharma Corporation
Werewolf Therapeutics, Inc.
Acerta Pharma BV
AstraZeneca
Ohio State University Comprehensive Cancer Center
University of Michigan Rogel Cancer Center
National Cancer Institute (NCI)
Incyte Corporation
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Dana-Farber Cancer Institute
UNC Lineberger Comprehensive Cancer Center
Fred Hutchinson Cancer Center
Incyte Corporation
M.D. Anderson Cancer Center
BeOne Medicines
St. Jude Children's Research Hospital
Memorial Sloan Kettering Cancer Center
Fondazione Italiana Linfomi - ETS
Bambino Gesù Hospital and Research Institute
St. Jude Children's Research Hospital